Rodríguez NE, Morfín OR

Idioma: Español
Referencias bibliográficas: 17
Paginas: 219-221
Archivo PDF: 25.53 Kb.

FRAGMENTO

Entre los microorganismos que infectan al ser humano, el Staphylococcus aureus (estafilococo dorado) es la bacteria más identificada por la población y el personal del sector salud.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Archer GL. Staphylococcus aureus: A well-armed pathogen. Clin Infect Dis 1998;26:1179-81.

2. Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998;26:1204-14.

3. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.

4. Nosocomial enterococci resistant to vancomycin, United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:579-97.

5. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb Mortal Wkly Rep 1997;46:624-6.

6. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.

7. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6.

8. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.

9. Ploy MC, Grelaud C, Martin C. First clinical isolate of vancomycinintermediate Staphylococcus aureus in a French Hospital. Lancet 1998:351-1212.

10. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.

11. Sierarzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.

12. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.

13. Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:626-8.

14. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus. J Infect Dis 1990;162:103-8.

15. Moreira B, Byle-Vavra S, DeJonge BLM, Daum RS. Increased production of penicillin-blinding protein 2, increased detection of other penicillin-blinding proteins and decreased coagulase activity associated with glucopeptide resistance Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1788-93.

16. Jarvis WR. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis 1998;26:1200-3.

17. Moellering RC. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-7.